Spyre Therapeutics Inc (SYRE)

$12.67 +0.25 (2.01%)
Market Cap 763.70M
Revenue (ttm) 0.00
Net Income (ttm) -208.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 740,100
Avg Vol 734,622
Day's Range N/A - N/A
Shares Out 60.28M
Stochastic %K 62%
Beta 3.05
Analysts Strong Sell
Price Target $54.10

Latest News on SYRE

Spyre Therapeutics Announces Grants of Inducement Awards

Apr 4, 2025, 4:05 PM EDT - 16 days ago

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Mar 27, 2025, 4:05 PM EDT - 24 days ago

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Mar 4, 2025, 4:51 AM EST - 6 weeks ago

Spyre Therapeutics: Targeting The Future Of IBD Treatment

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Feb 27, 2025, 4:05 PM EST - 7 weeks ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Feb 25, 2025, 8:00 AM EST - 7 weeks ago

Spyre Therapeutics to Participate in Upcoming March Investor Conferences

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Feb 19, 2025, 8:00 AM EST - 2 months ago

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Jan 13, 2025, 8:00 AM EST - 3 months ago

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Dec 18, 2024, 8:00 AM EST - 4 months ago

Spyre Therapeutics Added to the Nasdaq Biotechnology Index

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Dec 4, 2024, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Shareholders to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Dec 3, 2024, 10:00 AM EST - 4 months ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Dec 2, 2024, 10:00 AM EST - 4 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Shareholders to Inquire about Securities Investigation

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Dec 2, 2024, 8:00 AM EST - 4 months ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Dec 1, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Nov 29, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Nov 28, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Investors to Learn More About the Investigation

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Nov 27, 2024, 10:00 AM EST - 5 months ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Nov 26, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Connect

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 25, 2024, 5:11 PM EST - 5 months ago

Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Nov 25, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Spyre Therapeutics, Inc. (SYRE) And Encourages Stockholders to Connect

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Nov 24, 2024, 10:00 AM EST - 5 months ago

Spyre Therapeutics, Inc. (SYRE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Nov 22, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Spyre Therapeutics, Inc. (SYRE) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Nov 21, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Spyre Therapeutics, Inc. (SYRE) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Nov 20, 2024, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Spyre Therapeutics, Inc. (SYRE) And Encourages Investors to Reach Out

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Nov 18, 2024, 9:18 PM EST - 5 months ago

Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Nov 18, 2024, 4:14 PM EST - 5 months ago

Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Nov 12, 2024, 7:30 AM EST - 5 months ago

Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the Potential for Both Q3M & Q6M Maintenance Dosing

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Nov 11, 2024, 4:05 PM EST - 5 months ago

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 7, 2024, 4:05 PM EST - 5 months ago

Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Oct 30, 2024, 4:05 PM EDT - 6 months ago

Spyre Therapeutics to Participate in Upcoming November Investor Conferences

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

Oct 14, 2024, 8:00 AM EDT - 6 months ago

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Oct 1, 2024, 3:29 PM EDT - 7 months ago

Spyre: Extended Half-Life Tech To Become Differentiating Factor For IBD Targeting

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Oct 1, 2024, 8:00 AM EDT - 7 months ago

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer

Spyre Therapeutics to Participate in Upcoming Investor Conference

Sep 10, 2024, 4:47 PM EDT - 7 months ago

Spyre Therapeutics to Participate in Upcoming Investor Conference

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 7, 2024, 4:05 PM EDT - 9 months ago

Spyre Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Jun 18, 2024, 7:30 AM EDT - 10 months ago

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 29, 2024, 8:30 AM EDT - 11 months ago

Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

May 15, 2024, 7:30 AM EDT - 1 year ago

Spyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of Directors

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 4:02 PM EDT - 1 year ago

Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces $180 Million Private Placement

Mar 18, 2024, 8:00 AM EDT - 1 year ago

Spyre Therapeutics Announces $180 Million Private Placement

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 4:05 PM EST - 1 year ago

Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

Feb 26, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Feb 8, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Feb 5, 2024, 7:30 AM EST - 1 year ago

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors

Spyre Therapeutics to Present at Upcoming Investor Conference

Nov 28, 2023, 8:00 AM EST - 1 year ago

Spyre Therapeutics to Present at Upcoming Investor Conference

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD

Nov 27, 2023, 8:30 AM EST - 1 year ago

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD